MONMOUTH JUNCTION, N.J.,
March 7, 2017 /PRNewswire/ --
CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader commercializing its CytoSorb® blood
purification technology to treat deadly inflammation in
critically-ill and cardiac surgery patients around the world,
highlights planned activities at the 22nd International
Conference on Advances in Critical Care Nephrology (AKI & CRRT
2017) in San Diego, California,
starting today through March 10,
2017. AKI & CRRT 2017 is one of the premier international
conferences that covers blood purification in the intensive care
unit and draws global participation from critical care
nephrologists and intensivists worldwide.
Wednesday, March 8, 2017 –
Regular Conference Agenda
12:30 -
2:00PM
Extracorporeal support for Multi-organ
Failure: Emerging Strategies
Chair: Dr.
Patrick Honoré, Brussels, Belgium
- Sorbents from Bench to Bedside
Dr. Claudio Ronco – Vincenza, Italy
- ECMO and CRRT
Dr. David
Askenazi – Birmingham,
USA
- Sorbent Based Therapy
Dr. John Kellum – Pittsburgh, USA
Thursday, March 09, 2017 –
Company Sponsored Agenda
12:15 - 13:45 PM - Coronado Ballroom
AB
Regain Control – Polymer based hemoadsorption in SIRS,
Sepsis and Rhabdomyolysis
Chair: Dr. John Kellum and Prof. Dr. med. Steffen Mitzner
- The impact of hemoadsorption on cytokine removal and
immune response
Dr. John
Kellum, Pittsburgh,
USA
- Safety and efficacy of hemoadsorption – Clinical
experiences and evidence
Prof. Dr. med. Steffen Mitzner, Rostock, Germany
- New perspectives in the treatment of severe
rhabdomyolysis
Dr. Jacques
Duranteau, Paris,
France
In addition, the company has been selected to present short
poster presentations on the following submitted and accepted
posters:
- A novel adsorbent system rapidly clears verapamil from human
blood
- A novel adsorbent system rapidly clears amlodipine from
human blood
- Broad adsorption of sepsis-related pathogen and
damage-associated inflammatory mediators from whole blood using
porous sorbent beads
Please visit the company at its exhibit booth (Booth #2), where
representatives will discuss the role that CytoSorb plays in the
treatment of a variety of conditions in the intensive care unit
(ICU) such as sepsis, trauma, respiratory failure, liver failure,
post-operative complications, severe acute pancreatitis, and many
others.
About AKI & CRRT 2017
AKI & CRRT 2017 is intended to provide comprehensive
coverage of the rapidly developing field of Critical Care
Nephrology and Continuous Renal Replacement Therapy (CRRT).
It will highlight the recent advances in the understanding of the
pathophysiology of critical illness, acute kidney injury (AKI),
emerging strategies in the management of sepsis, multi-organ
failure, development and use of biomarkers, technical advances in
CRRT, and the appropriate utilization of these techniques.
The program presents exciting new developments and evidence for
assessing critically-ill patients, pathophysiology of liver
dysfunction and AKI using a mix of invited lectures, interactive
workshops, tutorials, poster sessions and panel discussions.
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 42 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury and pancreatitis, as well as in cancer immunotherapy. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used during and
after cardiac surgery to remove inflammatory mediators, such as
cytokines and free hemoglobin, which can lead to post-operative
complications, including multiple organ failure. CytoSorbents has
completed its REFRESH (REduction in FREe Hemoglobin) I trial - a
multi-center, randomized controlled study that has demonstrated the
safety of intra-operative CytoSorb® use in a heart-lung machine
during complex cardiac surgery. In 2017, the company plans to
initiate a pivotal REFRESH 2 trial intended to support U.S. FDA
approval. CytoSorb® has been used safely in more than 20,000
human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding in excess of $18 million from DARPA, the U.S. Army, the U.S.
Department of Health and Human Services, the National Institutes of
Health (NIH), National Heart, Lung, and Blood Institute (NHLBI),
U.S. Special Operations Command (SOCOM) and others. The Company has
numerous products under development based upon this unique blood
purification technology, protected by 31 issued U.S. patents and
multiple applications pending, including CytoSorb-XL, HemoDefend™,
VetResQ™, ContrastSorb, DrugSorb, and others. For more
information, please visit the Company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us
on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 3, 2017, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us
on Facebook and Twitter
Cytosorbents Contact:
Amy Vogel
Investor Relations
(732) 398-5394
avogel@cytosorbents.com
Public Relations Contact:
Amy Phillips
Pascale Communications
412-327-9499
amy@pascalecommunications.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-highlights-activities-at-the-22nd-international-conference-on-advances-in-critical-care-nephrology-300419180.html
SOURCE CytoSorbents Corporation